Abstract 155P
Background
Nuclear auto-antigenic sperm protein (NASP) is a histone chaperone and a facilitator of chromatin assembly. One of two NASP splice variants, tNASP, is specific to the testis, where it is sequestered by the blood-testis barrier and also present in cancer cells. Exposure of tNASP from the cancer cells to the immune system induces a robust humoral immune response. We hypothesized that the autoantibodies produced against tNASP may be used as a supplementary diagnostic marker for prostate, pancreatic, and ovarian cancer.
Methods
Sera from patients with pancreatic cancer (74), prostate cancer (63), and ovarian cancer (19) were tested for the presence of antibodies against tNASP using enzyme-linked immunosorbent assay (ELISA) with a recombinant tNASP fragment as bait. Correlation analysis was used to determine correlations between anti-tNASP antibody level and the age, ethnicity, TMN staging, and diagnostic marker levels (PSA in the prostate cancer and CA19-9 in pancreatic cancer).
Results
Level of anti-tNASP antibody in prostate cancer patients ranged from 426 to 3810 μg/mL and was significantly higher compared to healthy individuals (p<0.01). The cutoff for anti-tNASP antibody thus was established at 400 μg/mL. Combined analysis of anti-tNASP and PSA tests demonstrated that 18% of PC patients with PSA higher than 4 ng/mL had a low level of anti-tNASP antibody (false positive PSA, supported by negative biopsy); 11.4% of PC patients with PSA lower than 4 ng/mL had high levels of anti-tNASP antibodies (false negative PSA, proved histologically). Level of anti-tNASP antibody in pancreatic cancer patients ranged from 564 to 2751 μg/mL and was significantly higher compared to healthy individuals (p<0.01). Correlations between expression of tNASP antibody and levels of CA19-9 are not conclusive. There is a significant difference in tNASP antibody concentrations between serum from patients with ovarian cancer and serum from the control group of patients.
Conclusions
Expression of serum anti-tNASP antibody is not a specific screening marker for prostate, pancreatic, or ovarian cancer. Combined use of PSA with anti-tNASP antibody analysis reveals significant elimination of false positive and false negative PSA test results.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Campbell University, USA.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
197P - Clinical benefit of HER2-targeted therapies versus prior chemotherapy in refractory HER2 expressing and mutant gastrointestinal malignancies
Presenter: Vishesh Khanna
Session: Poster session 01
198P - Detection of ERBB2 (HER2) amplification by next-generation sequencing (NGS) in patients (pts) with gastrointestinal (GI) cancer
Presenter: Yunxiang Qi
Session: Poster session 01
199P - Novel machine learning (ML) algorithm to predict immunotherapy response in small cell (SCLC) and non-small cell (NSCLC) lung cancer
Presenter: Lakshya Sharma
Session: Poster session 01
200P - Precise tumor & patient selection for CDR404: A bispecific & bivalent MAGE-A4 T cell engager
Presenter: Giorgia Giacomazzi
Session: Poster session 01
201P - Afatinib for EGFR, HER2 or HER3 mutated solid tumors: A phase II Belgian precision study
Presenter: Lore Decoster
Session: Poster session 01
202P - Participant perceptions and mammography adherence from DETECT-A: The first prospective interventional trial of a multi-cancer early detection (MCED) blood test
Presenter: Nicholas Papadopoulos
Session: Poster session 01
203P - Genomic characterization of sporadic MET amplified non-small cell lung cancer (NSCLC) and association with real-world outcomes
Presenter: Ryan Gentzler
Session: Poster session 01
204P - Performance assessment of a comprehensive genomic profiling (CGP) NGS kit across multiple study laboratories
Presenter: Jonathan Choi
Session: Poster session 01
205P - A novel immunoprecipitation/PCR method for detection of plasma cfDNA fragments selectively occupied by CTCF in cancer
Presenter: Dorian Pamart
Session: Poster session 01
206P - WAYFIND-R: A global, real-world database of patients (pts) with a solid tumour profiled with next-generation sequencing (NGS)
Presenter: Jean-Yves Blay
Session: Poster session 01